Clodronate disodium is neither cytotoxic nor cytoprotective to normal and recombinant equine interleukin-1β-treated joint tissues in vitro.
Authors: Vergara-Hernandez Fernando B, Panek Char L, Nielsen Brian D, Robison Cara I, Colbath Aimee C
Journal: Veterinary surgery : VS
Summary
# Editorial Summary: Clodronate and Equine Joint Inflammation Bisphosphonates such as clodronate disodium have been explored as potential disease-modifying agents in equine joint disease, yet their direct effects on cartilage and synovial tissues remain poorly characterised. Vergara-Hernandez and colleagues conducted a rigorous in vitro study using chondrocytes, synoviocytes, and cartilage explants from three horses, exposing these tissues to clodronate at physiologically relevant concentrations (5–100 ng/ml) with and without recombinant interleukin-1β stimulation over 72 hours, then measuring inflammatory mediators (PGE₂, IL-6, nitric oxide) and cartilage degradation markers (glycosaminoglycans). IL-1β successfully induced a catabolic response with significantly elevated inflammatory markers and GAG release, confirming model validity, but clodronate neither suppressed this inflammatory cascade nor damaged healthy tissues at any concentration tested. The findings suggest that whilst clodronate appears safe for joint tissues, it lacks direct anti-inflammatory efficacy in this model and cannot be considered a disease-modifying treatment based on current evidence. Practitioners should be cautious about attributing anti-inflammatory benefits to clodronate intra-articular use until further in vivo studies clarify whether systemic administration or alternative formulations might yield different outcomes.
Read the full abstract on PubMed
Practical Takeaways
- •Clodronate disodium did not show protective or anti-inflammatory benefits in this in vitro model and should not be assumed effective for joint inflammation without further evidence
- •In vivo studies are needed before considering clodronate for equine joint disease, as this in vitro model suggests limited efficacy
- •Practitioners should be cautious about using clodronate as a standalone anti-inflammatory treatment for osteoarthritis or synovitis based on current evidence
Key Findings
- •IL-1β treatment significantly increased GAG, NO, PGE2, and IL-6 release, confirming catabolic effects on joint tissues (p < 0.05)
- •Clodronate disodium at concentrations of 5–100 ng/ml did not produce cytotoxic effects on chondrocytes, synoviocytes, or cartilage explants
- •Clodronate disodium failed to reduce inflammatory mediators (GAG, NO, PGE2, IL-6) in IL-1β-stimulated cultures regardless of dose tested
- •Current in vitro evidence does not support clodronate as an anti-inflammatory agent for equine joint disease